Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott and AstraZeneca have signed an agreement pursuant to which, Abbott will promote AstraZeneca's Crestor, a medication used along with diet to reduce high cholesterol.
Subscribe to our email newsletter
Under the terms of the agreement, Abbott will obtain the non-exclusive right to promote Crestor alongside AstraZeneca in the US, excluding Puerto Rico.
Crestor is a once-daily prescription statin medication indicated for use as an adjunct to diet in the treatment of various lipid disorders including primary hyperlipidemia, mixed dyslipidemia and isolated hypertriglyceridemia, and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. Crestor is available in a five, 10, 20, and 40mg dose.
Mike Tilton, vice president of primary care at AstraZeneca, said: “This agreement will allow AstraZeneca to increase share of voice for Crestor among physicians whose patients may benefit from this therapy.
“We see this as a good fit for both companies as this agreement allows us to leverage Abbott’s established presence in the dyslipidemia space.”